Curative Biotechnology's quarterly market cap
increased
from Sep. 2022 ($9.21 Mil) to Dec. 2022 ($11.59 Mil) and
increased
from Dec. 2022 ($11.59 Mil) to Mar. 2023 ($18.30 Mil).
Curative Biotechnology's annual market cap
increased
from Dec. 2020 ($10.06 Mil) to Dec. 2021 ($29.05 Mil) but then
declined
from Dec. 2021 ($29.05 Mil) to Dec. 2022 ($11.59 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Curative Biotechnology's Enterprise Value for Today is $6.90 Mil.
Curative Biotechnology (OTCPK:CUBT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Curative Biotechnology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curative Biotechnology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curative Biotechnology's Market Cap distribution charts can be found below:
* The bar in red indicates where Curative Biotechnology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Curative Biotechnology's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curative Biotechnology (CUBT) has a Market Cap of $6.90 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Curative Biotechnology and its competitors.
Is Curative Biotechnology's Market Cap too high?
Curative Biotechnology's current Market Cap is $6.90 Mil. The Biotechnology industry median Market Cap is 119.04. Curative Biotechnology's value of $6.90 Mil is 94.2% below this industry median.
How does Curative Biotechnology's Market Cap compare to ORGS and SNSE?
Curative Biotechnology's Market Cap of $6.90 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 119.04. Curative Biotechnology's value of $6.90 Mil is 94.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curative Biotechnology's current Market Cap of $6.90 Mil is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Curative Biotechnology and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curative Biotechnology's current Market Cap is $6.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current Market Cap of $6.90 Mil. The current Market Cap is $6.90 Mil and 94.2% below the Biotechnology industry median of 119.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current Market Cap is $6.90 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUBT has been successfully added to your 